OR

7

09 Nov 2010 12:03

DR LAURE PLASMATECHN

07114204829

se United States Application Number or PCT International

S. 1

Doc Code: Cath Document Description: Oath or declaration filed PTO/SB/01 (04-01) PTO(SB01) (04-01)

Approved for use binough decision(0, 04-0) (04-01)

U.S. Privati and Trackmark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Privati and Trackmark Office; U.S. DEPARTMENT OF COMMERCE

DECT: A Elia Track Comment of the Privation o Attorney Docket **DECLARATION FOR UTILITY OR** 14430 Number DESIGN First Named Inventor Dr. Stefan LAURE PATENT APPLICATION COMPLETE IF KNOWN (37 CFR 1,63) Application Number 10/586009 Declaration Submitted After Initial Submitted Filing (searche Filing Date With filth (37.CFR 1.16(f)) AR Unit required) Exeminer Name I hereby declare that: (1) Each inventor's recidence, making address, and citizenship are an stated below next to their name; and (2) I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and far which a patent is sought on the invention titled: PLASMA TREATMENT OF LARGE-SCALE COMPONENTS (Title of the Invention) the application of which is stracted hereto

Application Number 10/586009 _and was amended on (MM/DD/YYYY) (if applicable). I besoly state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I ecknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

Authorization To Permit Access To Application by Participating Offices

Was filed on (MMA/DDAYYYY) 07/11/2006

If checked, the undereigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (IPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (RIPO), and Japan Patent Critical Critical in Notes in transmission property Critical Property Critical Property Critical Property Critical Intellectual property critical in which is foreign application claiming priority to the above-identified patent application is filed access to the above-identified patent application. See 27 CFR 1.14(c) and (b). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming primity to the above-identified patent application is fied to have access to the above-identified patent application.

in accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above identified patent application with respect in socodaries with 37 CFR 1.14(1(3), section and no provided to a copy of the start in the shove-identified patent application—as filed; 2) any foreign application to which the shove-identified patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the loveign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application; and 3) any U.S. application—as filed from which benefit is sought in the above-identified palant application.

In accordance with 37 CFR 1.14(e), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices.

[Figs 1 of 2]
This badecism of information is required by 25 U.S.C. 115 and 37 CFR 1.93. The information is expansed to obtain or retain a benefit by the public selects by the U.S.P.D to proceed) on Ripticellon. Constituting its governed by \$6 U.S.C. 122 and 37 CFR 1.11 and 1.44. This constitute is estimated in taxes 21 minutes to complete, building, perioding, sand eubmidding the complete constituting the complete constituting the complete constitution from the term of the entered of driving pure required or the term and/or adjunctions for the RIPTID. Time tell vary depending upon the includant const. Assumed and Trindscaper's Office, U.S. Department of Commission, P.O. Box 1450, Alexandria, VA 22313.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SCHOTTE Commissionar for Particular, P.O. Box 1450, Alexandria, VA 22313.1450. DO NOT SEND FEES OR COMPLETED FORMS TO

If you need assistance in completing the torus eat \$-200-PTQ-9100 and select option 2.

09 Nov 2010 12:03 DR LAURE PLASMATECHN

07114204829

5.2

PTO/SE(or (04-05)
Approved for use through objection. ONE Office (04-05)
U.S. Peters and Tradertize Office; U.S. DEPARTMENT OF COMMISSION
U.S. DEPARTMENT OF DECLARATION — Utility or Design Patent Application Citim of Poreign Priority Sensitis I hereby claim foreign priority benefits under 35 U.S.C. 148(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at teast one country other than the United Stress of America, letted below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a fifing date before that of the application on which priority is claimed. Prior Foreign Application Foreign Filing Date Priority Centried Copy Attached? Country Number(s) (MAN/DOYYYY) Not Claimed 102004002878,8 DΕ 01/15/2004

[Page 2 of 3)

Additional foreign application number(s) are listed on a supplemental priority data sheet PTO/SB/02B attached hardto.

09 Nov 2010 12:03

DR LAURE PLASMATECHN

07114204829

8.3

PTO/38/01 (04-08) Approved for use theough asragators. CMB 0851-0025

LLS. Patient and Trademark Ottos; U.S. ESPARTIMENT OF COMMERCE

Underthe Papersonk Reduction Act of 1895, no persons are required to respond to a collection of intermedian unless it contains a welld CMB contain number. DECLARATION — Utility or Design Patent Application The address Correspondence associated with 61142 OR correspondence to: address helow Customer Number: Name Address Cay Вы Country Emat WARNING: Petitioned applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify that. Personal information such as social searity numbers, bank account numbers, or credit card numbers (other han a check or credit card authorization form PTC-2038 submitted for payment purposes) is never required by the USPTO to support a publish or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redaming such personal information from the documents before submitting them to the USPTO. Petitioners/applicant is advised that the record of a petent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(e) by made in the application) or issuance of a patient. Purifernore, the record from an abandonad application may also be available to the public if the application is referenced in a published application or an issuand patient (see 37 CFR 1.14). Chacks and credit credit authorization forms PTO-2038 automated for payment purposes are not retained in the application file and therefore are not publicly available. Pro-2030 stormant or payment purposes are not reterined in the approximation and are successful at the provided payment which form the record of a patent application (such as the PTO/SB/01) are placed into the Privacy Act system of records DEPARTMENT OF COMMERCE, COMMERCE-PAT-7, System name: Patent Application Files. Decuments not retained in an application file (such as the PTO-2038) are placed into the Privacy Act system of COMMISERCE/PAT-TM-10, System name: Deposit Accounts and Electronic Funds Transfer Profiles. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and bettef are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are purishable by time or imprisonment, or both, under 18 U.S.C. 1001 and that such within takes statements. may jeopardize the validity of the application or any peters issued thereon. NAME OF SOLE OR FIRST DOVENTOR: A petition has been filed for this unsigned inventor Given Name (first and middle (if any)) Family Name or Surname Dr. Stefan LAURE Inventor's Signature 09 November 2010 Country Chizanship Stuttgart DE DE Mairing Address Schwanenstrasse 12 City Zb Country Stuttgart 70329 DE Additional (resenters of a stope representative are being resented on the supplemental abanque PTO/SR/02A or UZLR educated horses

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-878) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 36 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the President of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing courset in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty
- World intellectual Property Organization, pursuant to the Patent Cooperation Treaty.

 6. A report in this system of records may be disclosed, as a routine use, to enother federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designes, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce)
- directive. Such disclosure shall not be used to make determinations about individuals.

 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 161. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in an application which became shandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.